PayerTalkCE® Presents: Understanding T2 Inflammation: Atopic Dermatitis

Track 1 - Spotlight on Atopic Dermatitis Infographic
Track 2 - Best Practices in Atopic Dermatitis Management Infographic

Release Date: January 31, 2025
Expiration Date: July 31, 2026
Estimated Time to Complete Activity: 0.5 hours per track
Compatible with all modern browsers and mobile devices

Expert Faculty Presenters


	Dana McCormick, RPh, FAMCP Senior Director, Pharmacy Advisory Services Optum Insights Click here for biography

	Shawn G. Kwatra, MD Chair, Department of Dermatology and Chief of Service of Dermatology University of Maryland Medical Center (UMMC) Click here for biography

	Drake Reiter, PharmD Director, Pharmacy Operations Priority Health Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Despite significant advances in understanding of the underlying etiology of AD, there remains a need to improve the overall management of AD to gain better control of the disease and reduce its clinical and humanistic burden. New systemic therapies that specifically target cytokines reveal the importance of major T2 cytokines IL-4 and IL-13 in AD pathophysiology. However, managed care professionals lack knowledge of how T2 inflammation impacts AD and the appropriate treatments to manage these patients. In addition, managed care professionals lack competence to effectively employ care management strategies based on current evidence that can improve treatment access and overall quality of care for patients with AD.

Educational Objectives
After completing this activity, the participant should be better able to:

Describe how T2 inflammation plays a central role in atopic dermatitis pathophysiology
Summarize safety and efficacy of treatments for patients with atopic dermatitis
Assess payer care management initiatives and other opportunities to improve treatment access and overall quality of care based on current evidence from clinical trials and treatment guidelines

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates each enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track 1: 0.5 AMA PRA Category 1 Credit™
Track 2: 0.5 AMA PRA Category 1 Credit™

Continuing Pharmacy Education
PACE designates each continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Track 1: JA4008073-9999-25-017-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-018-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.

Continuing Nursing Education
The maximum number of hours awarded for each Continuing Nursing Education activity is 0.5 contact hour.

Track 1: Spotlight on Atopic Dermatitis Infographic – 0.5 contact hour
Track 2: Best Practices in Atopic Dermatitis Management Infographic – 0.5 contact hour

DISCLOSURE
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

*Name of Working Group Members/Planners*	*Reported Financial Relationship*
Dana McCormick, RPh, FAMCP	Nothing to report.
Shawn G. Kwatra, MD	Nothing to report.
Drake Reiter, PharmD	Nothing to report.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.